2cureX publishes interim report for the third quarter of 2020.
2cureX AB (“2cureX”) hereby publishes interim report for the third quarter of 2020. The interim report is available as an attached document as well as on the company’s website (www.2curex.com). Below follows a short summary of the report.CEO Ole Thastrup comments “IndiTreat® was officially launched for colorectal cancer at the end of the third quarter at the international cancer conference ESMO (Eur. Soc. Medical Oncology). Nine months of pre-launch activities in 2020 embedded the launch readiness in terms of product offering, pricing, and positioning in our commercial strategy and